Quadriplegia secondary to abiraterone-induced severe hypokalemia

Jignesh B. Rajvanshi; Manin D. Chaudhary; Priyanka D. Malekar; Nitin K. Singhal; Shirish S. Alurkar

doi:10.4103/sajc.sajc_343_18

View/Download PDF

Buy Reprints

PDF

Translate this page into:

Letter to the Editor

08 (

03

); 139-144

doi:

10.4103/sajc.sajc_343_18

Quadriplegia secondary to abiraterone-induced severe hypokalemia

Jignesh B. Rajvanshi¹, Manin D. Chaudhary¹, Priyanka D. Malekar², Nitin K. Singhal³, Shirish S. Alurkar^4,

1 DNB Medical Oncology Resident, Department of Medical Oncology, Apollo CBCC Cancer Care, Ahmedabad, Gujarat

2 DNB Surgical Oncology Resident, Department of Medical Oncology, Apollo CBCC Cancer Care, Ahmedabad, Gujarat

3 Consultant Surgical Oncology, Department of Medical Oncology, Apollo CBCC Cancer Care, Ahmedabad, Gujarat

4 Chief Director, Department of Medical Oncology, Apollo CBCC Cancer Care, Ahmedabad, Gujarat

*Corresponding author: Dr. Shirish S. Alurkar. ssalurkar@gmail.com

Published: 2020-12-21

MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Licence

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.

References

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983-92.
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377:352-60.
James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. STAMPEDE Investigators abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377:338.

Fulltext Views
14

PDF downloads
5

View/Download PDF
Download Citations

BibTeX
RIS

Show Sections

[1] de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.

[2] Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983-92.

[3] Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377:352-60.

[4] James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. STAMPEDE Investigators abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377:338.